[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Perspective_Tx Perspective Therapeutics Perspective Therapeutics posts on X about $catx, has been, germany, details on the most. They currently have XXX followers and X posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1684919119819251712/interactions)  - X Week XXXXX +464% - X Month XXXXX +510% - X Months XXXXX +149% - X Year XXXXX +1,018% ### Mentions: X [#](/creator/twitter::1684919119819251712/posts_active)  - X Week X +200% - X Month X +29% - X Months XX +83% - X Year XX +467% ### Followers: XXX [#](/creator/twitter::1684919119819251712/followers)  - X Month XXX +10% - X Months XXX +39% - X Year XXX +61% ### CreatorRank: undefined [#](/creator/twitter::1684919119819251712/influencer_rank)  ### Social Influence [#](/creator/twitter::1684919119819251712/influence) --- **Social category influence** [countries](/list/countries) XXXXX% **Social topic influence** [$catx](/topic/$catx) 100%, [has been](/topic/has-been) 33.33%, [germany](/topic/germany) 33.33%, [details on](/topic/details-on) XXXXX% **Top accounts mentioned or mentioned by** [@pharmanowglobal](/creator/undefined) ### Top Social Posts [#](/creator/twitter::1684919119819251712/posts) --- Top posts by engagements in the last XX hours "Were proud to be featured in @PharmaNowGlobal highlighting the first patient has been dosed in a new cohort of our Phase 1/2a trial exploring 212PbVMT01 in combination with a PD-1 inhibitor. For more details: $CATX #TargetedAlphaTherapy #oncology" [X Link](https://x.com/Perspective_Tx/status/1976395024179888295) [@Perspective_Tx](/creator/x/Perspective_Tx) 2025-10-09T21:11Z XXX followers, XXX engagements "We are on the ground at the European Society for Medical Oncology Congress 2025 (#ESMO25) in Berlin Germany We will be presenting updated interim results from our Phase 1/2a study of 212PbVMT--NET on Monday Oct. XX at 8:58AM CEST. For more: $CATX" [X Link](https://x.com/Perspective_Tx/status/1979995998479880556) [@Perspective_Tx](/creator/x/Perspective_Tx) 2025-10-19T19:40Z XXX followers, XXX engagements "Earlier today Perspective presented updated interim results from its Phase 1/2a study of 212PbVMT--NET at #ESMO25. There will be a conference call today to discuss the data at 8:30AM ET. For more details on the presentation and conference call: $CATX" [X Link](https://x.com/Perspective_Tx/status/1980236379188769246) [@Perspective_Tx](/creator/x/Perspective_Tx) 2025-10-20T11:35Z XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Perspective_Tx Perspective Therapeutics
Perspective Therapeutics posts on X about $catx, has been, germany, details on the most. They currently have XXX followers and X posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX +464%
- X Month XXXXX +510%
- X Months XXXXX +149%
- X Year XXXXX +1,018%
Mentions: X #
- X Week X +200%
- X Month X +29%
- X Months XX +83%
- X Year XX +467%
Followers: XXX #
- X Month XXX +10%
- X Months XXX +39%
- X Year XXX +61%
CreatorRank: undefined #
Social Influence #
Social category influence countries XXXXX%
Social topic influence $catx 100%, has been 33.33%, germany 33.33%, details on XXXXX%
Top accounts mentioned or mentioned by @pharmanowglobal
Top Social Posts #
Top posts by engagements in the last XX hours
"Were proud to be featured in @PharmaNowGlobal highlighting the first patient has been dosed in a new cohort of our Phase 1/2a trial exploring 212PbVMT01 in combination with a PD-1 inhibitor. For more details: $CATX #TargetedAlphaTherapy #oncology"
X Link @Perspective_Tx 2025-10-09T21:11Z XXX followers, XXX engagements
"We are on the ground at the European Society for Medical Oncology Congress 2025 (#ESMO25) in Berlin Germany We will be presenting updated interim results from our Phase 1/2a study of 212PbVMT--NET on Monday Oct. XX at 8:58AM CEST. For more: $CATX"
X Link @Perspective_Tx 2025-10-19T19:40Z XXX followers, XXX engagements
"Earlier today Perspective presented updated interim results from its Phase 1/2a study of 212PbVMT--NET at #ESMO25. There will be a conference call today to discuss the data at 8:30AM ET. For more details on the presentation and conference call: $CATX"
X Link @Perspective_Tx 2025-10-20T11:35Z XXX followers, XXX engagements